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Abstract
Background: Steroidogenic acute regulatory (StAR) protein related lipid transfer (START) domains are small globular
modules that form a cavity where lipids and lipid hormones bind. These domains can transport ligands to facilitate lipid
exchange between biological membranes, and they have been postulated to modulate the activity of other domains of the
protein in response to ligand binding. More than a dozen human genes encode START domains, and several of them are
implicated in a disease.
Principal Findings: We report crystal structures of the human STARD1, STARD5, STARD13 and STARD14 lipid transfer
domains. These represent four of the six functional classes of START domains.
Significance: Sequence alignments based on these and previously reported crystal structures define the structural
determinants of human START domains, both those related to structural framework and those involved in ligand specificity.
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Introduction
The START domain is a ubiquitous conserved module for
binding and transporting lipids [1]. Although the functions of most
START domain containing proteins remain unknown, some
regulate steroidogenesis and some are known to transfer lipids
between membranes. There are approximately 40 proteins
containing domains with START homology encoded in the
human genome. The most well-characterized START domain
containing proteins have been divided into 6 groups based on their
phylogenetic relationships [2,3], but additional members can be
assigned to most of these groups. Group 1 contains the name-
giving family member, steroidogenic acute regulatory protein
(StAR/STARD1), and STARD3. Both are cholesterol carriers,
and mutations in STARD1 cause congenital lipoid adrenal
hyperplasia. Group 2 consist of proteins containing only a START
domain; group 3 proteins are capable of binding different ligands,
such as phosphatidyl choline (STARD2/PCTP) and ceramides
(STARD11); group 4 proteins (DLC, or deleted in cancerous liver
cells) are frequently de-regulated in cancer and contain Rho-
GTPase activating domains; group 5 proteins contain two
thioesterase domains; and group 6 consists of only STARD9, a
4614-residue protein with unknown function, that contains a
kinesin motor domain at its N-terminus. Mitochondria contain at
least the group 2 phosphatidylcholine transfer protein STARD7,
and also the Coenzyme Q binding protein Coq10, which was
recently identified to contain a divergent START domain [4].
Structural analyses of START domains from groups 1–3 have
provided detailed insights into how these proteins sequester
specific lipids [5–9] (summarized in Table 1). The ,210 residue
globular START module is a curved b-sheet gripped by two a-
helices. The concave face of the b-sheet and the C-terminal a-
helix enclose a hydrophobic cavity that can accommodate lipid
molecules. Here we present crystal structures of four human
START domains, those of STARD1, STARD5, STARD13 and
STARD14/ACOT11. These structures extend our knowledge
onto group 4 and 5 START domains, and enable a family-wide
comparison of their lipid binding cavities. This structural
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30comparison also sheds light on the lipid specificity of START
proteins.
Results
We used a structural genomics approach to human START
domain containing proteins. Based on previously published crystal
structures multiple expression constructs were designed for
STARD1, STARD5, STARD7–11, STARD13 and STARD14.
Following recombinant protein production in E. coli, well-
diffracting crystals were obtained for the START domains of
STARD1, STARD5, STARD13 and STARD14 (Table 2). Their
crystal structures were solved and refined to between 2.0 and
3.4 A ˚ resolution (Table 3).
Despite the low sequence identity among the START domains
(Fig. 1) all structures show a conserved domain structure consisting
of an a/b ‘‘helix-grip’’: A curved antiparallel b-sheet on which two
helices near the N- and C-terminus are packed forming a cavity to
the concave side of the sheet (Fig. 2 and Datapack S1). The
backbone atoms of all four proteins superimpose with an rmsd of
2.3 A ˚ over 154 residues (Fig. 2F), and the backbone atoms of all
START domains included in Table 1 superimpose with an rmsd
of 2.3 A ˚ over 138 residues.
STARD1
We solved the crystal structure of STARD1, a member of the
StAR group, at a relatively low resolution of 3.4 A ˚ (Fig. 2B).
Table 1. Human START proteins, their ligands, and the available crystal structures.
Group Protein Ligand PDB entry
1 - StAR STARD1 cholesterol [5] 3P0L; ligand-free (this study)
STARD3/MLN64 cholesterol [5] 1EM2; ligand-free [5]
2 - START only STARD4 cholesterol [19] 1JSS (mouse); ligand-free [7]
STARD5 cholesterol, 25-hydroxycholesterol [19] 2R55; ligand-free (this study)
STARD6 cholesterol [40] -
3 - PCTP STARD2/PCTP phosphatidyl choline [41] 1LN1; DLP complex
1 [6]
STARD7 phosphatidyl choline [42] -
STARD10 phosphatidylcholine/ethanolamine [43] -
STARD11/CERT ceramides [8] 2E3R; C18-ceramide complex [8];
2Z9Z; C10-DAG complex
2 [8]; 3H3S;
H15 complex
3 [9] and 10 more
entries
4 - RhoGAP STARD8 charged lipid? -
STARD12 charged lipid? -
STARD13 charged lipid? 2PSO; ligand-free (this study)
5 - Thioesterase STARD14 fatty acid? 3FO5; PEG complex
4 (this study)
STARD15 fatty acid? -
6 - STARD9 STARD9 ? -
1DLP, 1,2-dilinoleoyl-SN-glycero-3-phosphocholine.
2DAG, diacylglycerol.
3H15, 3-hydroxy-1-(hydroxymethyl)-3- phenylpropyl]pentadecanamide.
4PEG, pentaethylene glycol.
doi:10.1371/journal.pone.0019521.t001
Table 2. Summary of crystallization and cryo conditions.
Condition
STARD1
native
STARD5
native
STARD13
native
STARD14
native
STARD14
SeMet
Salt 200 mM Ca-acetate - 125 mM NaCl 200 mM MgCl2 200 mM NaSCN
Precipitant 40% PEG-300 10% PEG-6000 20% MPD 25% PEG-3350 20% PEG-3350
Buffer 100 mM Na-cacodylate 100 mM HEPES 100 mM Tris-HCl 100 mM Bis-Tris
pH 6.5 7.0 8.0 5.5 6.9
Additive Cholesterol - - - -
Temperature 4uC4 uC4 uC4 uC4 uC
Method Sitting drop Sitting drop Hanging drop Sitting drop Sitting drop
Drop size (protein/well
solution) (ml)
0.2/0.2 0.8/0.4 0.8/0.2 0.2/0.2 0.2/0.4
Cryo additive 50% PEG-300 20% BD 40% MPD 20% Glycerol 18% Glycerol
doi:10.1371/journal.pone.0019521.t002
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the intriguing packing inside the lattice of these crystals: The
asymmetric unit consists of four molecules that are organized as a
long tube along the 63 axis (Fig. 3A). The inside diameter of the
tube is 75 A ˚, resulting in a solvent content of 60%.
Homology modeling and subsequent ligand docking trials were
previously studied in an effort to understand biological functions of
STARD1 [10]. The STARD1 crystal structure supports the
homology model (PDB 2I93). Superposition of the crystal structure
with the lowest energy homology model yields an rmsd of 1.5 A ˚
for 205 out of the 213 Ca atoms. Major differences between these
structures are found in the loops 191–196 and 209–215.
Cholesterol was included in the crystallization buffer. However,
additional density which was observed in the cavity did not match
the expected density of cholesterol. We believe that the cavity was
either empty or partially occupied by a small ligand derived from
the expression host or from the crystallization solution.
STARD5
STARD5 [11], a member of the START only group (Table 1),
binds specifically to cholesterol and 25-hydroxycholesterol. The
closest homolog of human STARD5 with a crystal structure
available in the PDB is mouse STARD4 [7], with 34% shared
sequence identity between the proteins. We also used this structure
of mouse STARD4 (PDB entry 1JSS) as a molecular replacement
model. Alignment of the refined structure with mouse STARD4
gives an rmsd of 1.3 A ˚ over 194 Ca-atoms. The STARD5
structure is naturally also closely related to other human START
domains (Fig. 2).
STARD13
The structure of human STARD13, a member of the RhoGAP
group, is also most similar to mouse STARD4, with an rmsd of
1.8 A ˚ for 164 Ca-atoms. The largest difference between
STARD13 and other START domain structures lies in the N-
terminal helix, which in STARD13 is swapped with the adjacent
protein in the crystal (Fig. 2D and 3B). The swapped helix
interacts with the expected area of the b-sheet, but runs in an
opposite direction. This surprising helix-swapping may be an
artifact of a truncated expression construct.
STARD14
T h ea s y m m e t r i cu n i to ft h ec r y s t a lo fS T A R D 1 4 / A C O T 1 1
contains a dimer. The large buried surface area between the
monomers (900 A ˚ 2 per monomer, as determined by the PISA server
[12]) indicates that this interaction could form also in solution.
However, the full-length protein likely forms a trimer in the
thioesterase domains of ACOT12 (PDB id. 3B7K), and the dimer
interface of truncated STARD14 may only be a part ofthe biologically
relevant assembly. The STARD14 structure differs slightly from the
other START domain structures in that the C-terminal consensus a-
helix is broken into two shorter helices (Fig. 1 and 2E).
The unique N-terminal helix (a0) of STARD14 (Fig. 2E) acts as
a linker to the thioesterase domains. Interestingly, this N-terminal
helix packs onto the C-terminal START domain helix (a49) that is
thought to undergo a conformational change upon ligand binding
[13]. Based on the crystal structure it is feasible that the N-
terminal helix upon ligand binding transmits a conformational
signal to the thioesterase domains to regulate its activity. Thus, our
results form a structural basis for interpreting the conformation of
the N-terminal helix. This however requires verification by
experiments with the full-length protein.
Family wide structural comparison
Human START domains share a significant but low sequence
identity (as low as 14%). As a consequence, homology-based
sequence alignment methods make prediction of the positions of
critical residues within the physiological START domain struc-
tures challenging. We generated a structure based sequence
alignment by superposing all known START domain structures,
and using this 3D alignment as a basis for aligning the sequences of
the human START domain classes. This method yielded an
improved alignment, and displayed similarities between individual
proteins that have been overlooked by homology based methods
(Fig. 1). When compared to previous family wide alignments [11]
it is evident that the structure-based alignment has the similar
overall features. It does not contain gaps within the secondary
structure elements thus providing better alignment when the
structure, but not necessarily the sequence, is conserved. On the
other hand our structure-based alignment could be misleading for
surface residues that are affected by crystal contacts, in particular
Table 3. Data collection statistics.
*
Protein STARD1 STARD5 STARD13 STARD14
STARD14 SeMet
pk
STARD14 SeMet
ip
STARD14
SeMet rm
X-ray source ESRF ID29 ESRF ID14.4 ESRF ID14.4 ESRF ID14-2 BESSY BL14-2 BESSY BL14-2 BESSY BL14-2
Wavelength (A ˚) 0.97948 1.03992 1.03992 0.93300 0.97973 0.97985 0.97201
Space group P63 P65 P43 C2221 P31 P31 P31
Cell dimensions
a, b, c (A ˚) 144.130, 144.130,
101.030
62.87, 62.87,
214.93
78.24, 78.24,
212.72
52.44, 130.08,
165.23
69.41, 69.41,
97.25
69.41, 69.41,
97.25
69.41, 69.41,
97.25
a, b, c (˚
) 90, 90, 120 90, 90, 120 90, 90, 90 90, 90, 90 90, 90, 120 90, 90, 120 90, 90, 120
Resolution (A ˚) 15-3.4 (3.5-3.4) 20-2.5 (2.6-2.5) 20-2.8 (2.9-2.8) 20-2.0 (2.1-2.0) 50-2.3 (2.36-2.3) 50-2.3 (2.36-2.3) 50-2.3 (2.36-2.3)
Rmerge
{ 0.173 (0.797) 0.102 (0.671) 0.038 (0.556) 0.055 (0.545) 0.040 (0.468) 0.037 (0.471) 0.036 (0.533)
I/(sI) 19.8 (4.8) 23.3 (5.9) 15.2 (3.7) 15.3 (2.6) 10.1 (1.6) 10.8 (1.6) 11.5 (1.4)
Completeness (%) 98.6 (100) 99.4 (99.5) 99.5 98.1 (99.5) 98.5 (97.9) 98.4 (97.8) 98.4 (97.5)
Redundancy 22.6 (22.8) 22.3 (22.1) 7.5 (7.7) 3.9 (3.9) 1.6 (1.6) 1.6 (1.6) 1.6 (1.6)
*Values for the highest resolution shell are shown in parentheses.
{Rmerge=Si |I i2ÆIæ |/S ÆIæ, where I is an individual intensity measurement and ÆIæ is the average intensity for this reflection with summation over all data.
doi:10.1371/journal.pone.0019521.t003
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These regions often contain gaps in the alignment.
Notably, there are three absolutely conserved residues (Trp96,
Trp147 and Arg217; STARD1 numbering) and a highly
conserved Asp183 that is replaced by the similar glutamate only
in STARD4 (Fig. 1). Trp96, Asp183 and Arg217 are all on the
‘‘back’’ face of the b-sheet (Fig. 4A): Asp183 and Arg217 form a
salt bridge, whereas Trp96 appears to be structurally important in
aligning the N-terminal helix onto the b-sheet. Trp147 is likely of
functional importance, specifically as a possible gate keeper in lipid
ligand loading. It is located in a helical loop region and interacts
with the C-terminal helix. In STARD1, the hydrophobic cluster
Figure 1. Structure based sequence alignment illustrating sequence conservation among human STARD proteins. Protein sequences
were aligned based on the available crystal structures as detailed in Materials and Methods. Secondary structure elements are shown on top of each
sequence for which a crystal structure is available, and a-helices are numbered. Secondary structural elements in the C-terminal section of STARD14
isoform are shown in grey to indicate their divergence. Asterisks following protein names indicate that crystal structures of human proteins are
available.
doi:10.1371/journal.pone.0019521.g001
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helix in a closed conformation [14]. Conservation of this structural
feature across the domain family indicates that a lipid binding
mechanism via local unfolding or a significant conformational
change in the C-terminal helix could be a family wide
phenomenon. Mutation in the adjacent, highly conserved residue
Asn148 has been observed in congenital lipoid adrenal hyperplasia
(lipoid CAH) [15], which add further evidence to the functional
importance of this region (Fig. 4B).
Lipoid CAH is linked also to other mutations in the STARD1
encoding gene. Some of these mutations lead to premature stop
codons, while others change the protein activities and lipid binding
Figure 2. Overview of the crystal structures reported in this study. (A) Cartoon of the START domains studied here in context of the
respective full-length proteins (drawn approximately to scale). (B–E) Side-by-side comparison of human STARD1, -5, -13, and -14 in a similar
orientation. All START domain structures are colored from the N-terminus (blue) to the C-terminus (red) and the linker to the N-terminal thioesterase
domain of STARD14 (panel E) is shown in grey. (F) Stereo view of a superposition of the backbone traces of the four crystal structures shown in panels
B through E (blue, STARD1; red, STARD5; cyan, STARD13; yellow, STARD14). The view is that of panels B–E with an approximately 90u rotation
downward toward the viewer.
doi:10.1371/journal.pone.0019521.g002
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the STARD1 structure, it is evident that these changes occur in
structurally important residues (Fig. 4B). However, with the
exception of Asn148, the affected residues are not conserved across
the family (Fig. 1). Most of the point mutations are in the C-
terminal helix lining the ligand binding cleft or in residues
interacting with this helix. These mutations would therefore cause
changes in the dynamics of the ligand binding. It has been
suggested that the C-terminal helix would undergo unfolding
during ligand binding, and this suggestion is supported by the
effects of the lipoid CAH mutations near the C-terminal helix [14].
The model of helix unfolding during cholesterol binding has been
recently reviewed [17]. Some residues mutated in lipoid CAH are
surface exposed indicating that they may change other interactions
of the protein molecule as suggested for a gain of function
mutation Q128R [15]. Also R182L is able to bind cholesterol but
does not have ‘‘star-like activity’’ [18].
Cavity sizes in the known START proteins vary from 873 A ˚ 3 to
2297 A ˚ 3 (based on the molecular surfaces of ligand bound as well
as ligand free structures). STARD14 has clearly smallest cavity of
the family. Cholesterol binding START domains have cavity sizes
of 1014–1122 A ˚ 3, which is close to the size of the natural ligand.
The largest cavity is observed for STARD2, which also binds
larger ligand than other characterized members of the family
(Table 1, Fig. 5). It is possible that the shape of the cavity changes
upon ligand binding and therefore the size of the cavity is not
directly related to the size of the ligands. However, together with a
structure based sequence alignment, the cavity sizes suggest key
residues and structural determinants of ligand binding and
selectivity.
Figure 3. Notable properties of the STARD1 and STARD13 crystals. (A) Packing of STARD1 in the crystal lattice with the tube formed around
the 63-axis. Monomers A–D in the asymmetric unit are colored individually, and symmetry generated molecules around the axis are shown. (B)
STARD13 structure displaying the N-terminal helix swap with the adjacent protein molecule in the crystal. Two monomers (blue and white) are shown
and the N-terminal helix of a third monomer is shown in magenta. Side chains are displayed for one of the C-terminal helices.
doi:10.1371/journal.pone.0019521.g003
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Inspection of the ligand cavity of ligand free STARD1 suggests
Glu169, Arg188, Leu199 and His220 as key residues in cholesterol
binding. These side chains will likely change conformation upon
ligand binding. Notably only His220 is conserved among the
cholesterol binding members. Ligand docking predicted choles-
terol binding to STARD1 involves a hydrogen bond between the
cholesterol hydroxyl and either the Arg188 side chain or the
backbone carbonyl of Leu199 [10]. Either of these ligand binding
modes is consistent with the present STARD1 crystal structure.
START only - STARD5
In order to understand ligand binding in STARD5, we docked a
cholesterol molecule to the binding cavity of the STARD5
structure. All the top ranked binding modes had cholesterol in
the so-called ‘‘IN’’ conformation, with the hydroxyl group of
cholesterol pointing towards the cavity (Fig. 6A). The binding
mode is similar to the one predicted for other START domains
[10]. In this scenario, the Ser132
199 hydroxyl forms a hydrogen
bond to the cholesterol hydroxyl in our best docking scenes as
predicted for STARD3 (superscript numbering denotes positions
in STARD1; see Fig. 1). A serine in this position is conserved in
the cholesterol binding STARD3, -4 and -5, and there is a serine
residue in the adjacent position in STARD6 that might fulfill the
same function (Fig. 1). In all other START domain subfamilies
there are hydrophobic residues at this position. Despite the
conservation of this serine side chain within the cholesterol binding
subclass, there is no similar serine in STARD1. Thus, in the
absence of a START domain-cholesterol complex structure, the
accurate binding mode of cholesterol can not be resolved.
STARD5, in contrast to STARD1, can also bind 25-hydro-
xycholesterol[19].Thecrystalstructure and dockingmodelsuggests
a structural basis for binding specificity towards this ligand: The
additional hydroxyl group is attached to a flexible hydrophobic tail
of cholesterol, and this hydroxyl could be positioned within
hydrogen bonding distance of the side chain of Thr103
171 in
Figure 4. Sequence conservation among human STARD proteins. (A) Positions of strictly conserved residues, as identified by the alignment
shown in Figure 1, mapped onto the structure of STARD1 (pdb entry 3P0L). (B) Residues mutated in CAH shown as side chains in the STARD1
structure.
doi:10.1371/journal.pone.0019521.g004
Figure 5. Ligand binding in START domains. Side-by-side comparison of the structures that have been solved with a ligand bound in the cavity:
(A) STARD2 (1LN1) with 1,2-dilinoleoyl-SN-glycero-3-phosphocholine (DLP); (B) STARD11 (2E3R) C16-ceramide; (C) STARD14 (3FO5) with PEG or
putative fatty acid.
doi:10.1371/journal.pone.0019521.g005
Crystal Structures of Human START Domains
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e19521STARD5 (Fig. 6A). In STARD1 the corresponding residue is
alanine and together with the missing serine side chain (Ser132
199)
at the bottom of the cavity this could cause different ligand binding
modes in STARD1 and STARD5, as discussed above.
RhoGAP group - STARD13
The natural ligand of STARD13 is unknown. We looked to
identify possible ligands based on the STARD13 side chains at the
positions that correspond to those involved in lipid binding in
other family members. From the crystal complexes of STARD11
and ceramides we know that Arg442
144 and Glu446
148 are the
only conserved residues between the proteins making contacts with
ceramide, Glu446
148 being the most critical [8]. Notably, the
STARD13 cavity also contains more polar side chains (three
arginines, three histidines, an aspartate, a glutamate, two cystines
and two tyrosines) compared to the cholesterol binding members,
and the putative cholesterol hydroxyl binding Ser132
199 of
START5 is not conserved. The STARD13 cavity shares some
characteristics with the members of the thioesterase group
(discussed below). Intriguingly, some of the side chains that are
involved in the interaction of STARD2 with dilinoleoylpho-
sphatidylcholine are conserved in STARD13 (Fig. 6B): Arg974
144
and Asp978
148 are conserved in the corresponding position;
Tyr999
169 replaces Trp101
169, Tyr1054
225 replaces Tyr72
137 and
His1068
241 replaces Gln157
223. These side chains are also
conserved in STARD8 of the same group, but not all in
STARD12 (Fig. 1). Together, these properties indicate that
STARD13 may bind a charged lipid.
Notably, the ligand binding cavity of STARD13 is smaller than
that of STARD2 and elongated, with a small maximum diameter
(Fig. 6B). This causes clashes between phosphatidylcholine and the
C-terminal helix of STARD13 when the two structures are
superposed. Upon ligand binding, the STARD13 cavity could
expand due to movement of the C-terminal helix. The crystal
structure however indicates that the natural ligand would be small
– perhaps a fatty acid as proposed here for STARD14.
Thioesterase group – STARD14
The lipid binding cavity of STARD14 is rather hydrophobic as
it is lined by phenylalanine, valine, leucine and isoleucine side
chains. The cavity also contains patches of charged and
hydrophilic residues, possibly making specific interactions with
an unknown ligand. Inside the STARD14 cavity we observed a
continuous electron density that by its shape resembles a fatty acid
(Fig. 6C). In the monomer B of the asymmetric unit the density
was more continuous. In addition to the STARD14 model
discussed here, the fatty acid-like density was present also in two
other data sets that originated from different STARD14 protein
constructs crystallized in different space groups (not shown).
Despite several attempts with different strategies we could not
identify the ligand by mass spectrometry. Therefore we modeled
the density as a polyethylene glycol (PEG) fragment in the
published model. Nevertheless, we believe that the natural ligands
of STARD14 isoforms may be fatty acids based on several lines of
evidence: (i) The cavity and conserved residues lining it are not
consistent with the known START domain ligands cholesterol,
phosphatidylcholine or ceramides. (ii) As STARD14 also contains
the acyl-CoA thioesterase domains, fatty acid binding to the
START domain might be physiologically meaningful. (iii) The rat
ortholog of STARD14 has acyl-CoA thioesterase activity with
specificity towards medium to long-chain (C12–18) fatty acyl-CoA
substrates [20] and the STARD14 structure appears compatible
for binding fatty acids containing up to 18 carbon atoms.
The STARD14 structure is expanded in comparison to the
empty START domain structures, although the C-terminal helices
are in a similar position as the C-terminal helix of STARD2 solved
in complex with phosphatidylcholine. Possibly BFIT1 and BFIT2,
the isoforms of STARD14, could have different ligand specificity.
The crystallized form (BFIT2) contains two helices at the C-
terminus whereas BFIT1 probably has only one, as seen in other
START domains (Fig. 2). Interestingly, BFIT2 is more similar to
STARD15 than BFIT1 (Fig. 1). The residues that would bind the
putative head group of the fatty acid, Arg449
144 and Tyr546
241,
are conserved in STARD15. Tyr546
241 is a tryptophan in BFIT1
and Tyr456
151 is phenylalanine in STARD15 (Fig. 1 and 6C).
Other interactions around the PEG molecule found in the
structure do not appear to be strictly conserved; however if the
ligand is a fatty acid, these interactions are likely not specific and
the selectivity would be accomplished based on the shape of the
cavity rather than by specific side chain interactions.
Discussion
A structure based alignment reveals important features within
the START domain subfamilies, and highlights critical conserved
Figure 6. Ligand binding cavity of STARD5, -13, and -14. (A) Model of cholesterol binding to STARD5. (B) Lipid binding cavity of STARD13, with
the cavity inner surface indicated in the background (magenta). Side chains that are conserved and structurally complementary among STARD13
(blue) and STARD2 (grey) are shown as sticks. The C-terminal helix of STARD13 is shown as a blue cartoon to illustrate clashes with the STARD2 ligand.
(C) Ligand binding to STARD14. Difference density is contoured at 2s around the modeled PEG molecule in monomer B to show the elongated shape
with density for the head group resembling a carboxyl group.
doi:10.1371/journal.pone.0019521.g006
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scope of this paper are STARD13 and STARD14, the family
members for which the ligands are not known. STARD13
Arg974/STARD14 Arg449
144 is highly conserved (Fig. 1) and is
likely a key residue binding negatively charged lipids such as
phosphatidylcholine and fatty acids. This is complemented by a
negatively charged residue at position 148. This is generally an
aspartate, but in STARD11 it is the longer glutamate, which
makes important hydrogen bonds to the bound ceramide.
Notably, these residues are not conserved in the StAR nor in
the STARD9 groups. In the StAR group there is a similar ion pair
between the b–strands, namely, Glu169 and Arg188, which is not
found in other family members that bind cholesterol. Arg188 has
been suggested to bind to the hydroxyl group of cholesterol and it
is also present in PCTP and RhoGAP groups. Trp147 is absolutely
conserved across the family, and since the Trp147 side chain
interacts with hydrophobic residues of the C-terminal helix in all
the structures (Fig. 4), this region is likely important for lipid access
to the cavity. Our structural analysis also suggests that the cavities
can adjust to binding several types of lipids due to their flexibility
and hydrophobic nature, while the small differences in the key
conserved residues make them specific towards different lipids.
The third helix is likely also important for the lipid binding
mechanism as it interacts with the C-terminal helix proposed to
partially unfold during lipid binding.
Conclusions
The crystal structures reported here help to gain a family wide
understanding of the structural determinants within the START
domain family. Use of these results to create a structure-based
alignment helped to determine the conserved features within the
family which are overlooked by sequence homology based methods.
Many human START domains have unknown functions and their
apo-structures form a structural basis for ligand identification thereby
providing new leads to biological functions. All structures reported are
relevant to disease. They are down- (STARD13) or up-regulated
(STARD5) in cancers, mutations in them result in metabolic disorders
(STARD1) or they are linked to obesity (STARD14; [21]). Based on
our structural analysis we propose charged lipids as ligands for
STARD13 and fatty acids as ligands for STARD14.
Materials and Methods
Cloning
The cDNAs coding for full-length human STARD1, STARD5,
and STARD14 were obtained from the Mammalian Gene
Collection (accession codes BC010550, BC004365 and
BC093846, respectively). The cDNA encoding full-length human
STARD13 was PCR amplified from pooled human brain, liver,
placenta, and thymus cDNA libraries (Ambion). The sequence
coding for residues STARD1
T66-R284, STARD5
A6-E213,
STARD13
E51-I264, and STARD14
R339-L594 were subcloned into
expression vector pNIC-Bsa4 by ligation-independent cloning.
The resulting expression constructs contained a hexahistidine tag
and a TEV-protease cleavage site (MHHHHHHSSGVDLGT-
ENLYFQS) at the N-terminus.
Protein expression and purification
Each expression construct was transformed into E. coli strain
BL21(DE3)R3 pRARE (Novagen). Cultivation was done in a LEX
large-scale expression system (Harbinger Biotechnology & Engi-
neering). Cells were grown in Terrific Broth supplemented with
8 g/l of glycerol and 100 ml/l BREOX antifoam agent at 37uC. At
an OD600 nm of between 1 and 2 the temperature was lowered to
18uC, recombinant protein production was induced by addition of
0.5 mM isopropyl-b-d-thiogalactopyranoside, and cell growth was
continued for 18 h. Cells were harvested by centrifugation and
resuspended in 1.5 ml of buffer 1 per gram of wet cells (30 or
50 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 10 mM
imidazole, 0.5 mM TCEP). Before lysis, 4 ml (1000 U) of
Benzonase (Novagen) and one tablet of Complete EDTA-free
protease inhibitor (Roche Biosciences) were added per 50 ml cell
suspension, and cells were lysed by a freeze-thaw cycle and
sonication. Cell debris was removed by centrifugation and the
soluble fractions were filtered through a syringe filter (0.45 mm
pore size). Cleared cell lysates were passed over 1-ml HiTrap
Chelating columns (GE Healthcare) pre-equilibrated with buffer 1.
The columns were washed sequentially with buffer 1 and buffer 1
containing 25 mM imidazole. Bound protein was eluted with
buffer 1 containing 500 mM imidazole and loaded onto 16/60
HiLoad Superdex-75 columns (GE Healthcare). Gel filtration was
performed in buffer 2 (30 mM HEPES or 30 mM sodium
phosphate, pH 7.5, 300 mM NaCl, 10% glycerol, 0.5 mM
TCEP). Fractions were pooled based on gel filtration profiles
and purity determined by SDS-PAGE and Coomassie staining.
STARD1 and STARD14 proteins were liberated from the
hexahistidine tag by incubation with His6-tagged TEV-protease
(20:1 molar ratio) over night at room temperature and subsequent
passage over 1-ml HiTrap Chelating columns. The proteins were
concentrated to 28.2 mg/ml (STARD1), 21.8 mg/ml (STARD5),
4.3 mg/ml (STARD13), and 11.3 mg/ml (STARD14) using spin
concentrators. TCEP was added to a final concentration of 2 mM
and aliquots were flash-frozen and stored at 280uC. Proteins were
typically more than 90% pure judged by SDS-PAGE analysis.
Protein construct masses were verified by TOF-MS analysis.
Crystallization and data collection
Crystallization was done by the sitting or hanging drop vapor
diffusion method. Proteins in gel filtration buffer were mixed with
reservoir solution (see Table 2 for details). For data collection
crystals were briefly dipped in cryo solution supplemented with
suitable additives (Table 2) and flash-frozen in liquid nitrogen.
Synchrotron radiation datasets were collected at ESRF,
Grenoble, France and at BESSY, Berlin, Germany. Data sets
were indexed, scaled, and reduced using XDS (Table 3) [22].
Structure solution
Details of the structures are given in Table 4. The STARD1
structure was solved by molecular replacement with MOLREP
included in the CCP4 suite [23] using the STARD3 (1EM2)
structure as a model. MOLREP placed the first two molecules in
the asymmetric unit and a third one after refinement. The fourth
monomer was placed manually, using a helix density as guide,
followed by a rigid body refinement in PHENIX [24]. A test set of
reflections for STARD1 was selected with PHENIX to prevent
creation of a biased set due to twinning. Twin refinement with
operator h,-h-k,-l was done with PHENIX and the refined twin
fraction was 0.149. This is in agreement with the estimated twin
fraction using the diffraction data only (0.130). Model building was
done with COOT [25].
The STARD5 structure was solved by molecular replacement
with MOLREP [26] using pdb entry 1JSS as a model. The
structure was refined initially with PHENIX and in the final stages
with REFMAC5. TLS model consisting of 3 groups per monomer
was used based on the suggestion by the TLSMD server [27].
STARD13 was solved by molecular replacement with
MRBUMP [28] using pdb entry 1JSS as a model. The model
was edited with CHAINSAW [29] and the best solution, with two
Crystal Structures of Human START Domains
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After rigorous editing and refinement with PHENIX a third
molecule was located with MOLREP using partially refined
monomer as an input. Model building was done with COOT and
REFMAC5 was used in the final refinement cycles.
The STARD14 structure was solved using Solve [31] with the
three-wavelength MAD data. Resolve [32] was used to build the
initial model, which was then improved by cycles of manual editing
and PHENIX autobuild. The asymmetric unit consisted of two
chains and one of them was used as a model in MOLREP using the
native data. The model was further improved by 3 rounds of
manualmodelbuildingandautomated buildingwitharp-warp[33].
Final refinement cycles were done with REFMAC5.
Analysis of structures and visualization
Models were validated with Molprobity [34]. Initial structure
based sequence alignments were made with MultiProt [35] and
Staccato [36] using PDB entries 3P0L, 1LN1, 1EM2, 1JSS, 2R55,
2E30, 2PSO and 3FO5. The alignment was edited with Bodil [37]
(similarity matrix STRMAT110; minor manual edits) to include
full domain sequences, and visualized with Aline [38]. Cavity sizes
were calculated with CASTp [39]. The enhanced version of the
article was prepared with ICM (Molsoft).
Modelling
Docking of cholesterol to STARD5 structure was done with ICM
(Molsoft). Residues surrounding the cavity were selected to indicate
the binding site and initial docking of cholesterol was done keeping
the residues fixed. Best conformations were energy minimized with
ICM and the residues around the docked ligand were optimized.
Supporting Information
Datapack S1 Standalone iSee datapack - contains the
enhanced version of this article for use offline. This file
can be opened using free software available for down-
load at http://www.molsoft.com/icm_browser.html.
(ICB)
Text S1 Instructions for installation and use of the
required web plugin (to access the online enhanced
version of this article).
(PDF)
Acknowledgments
We gratefully acknowledge the beam line scientists at the BESSY and
ESRF synchrotron radiation facilities for expert assistance.
Author Contributions
Conceived and designed the experiments: AGT CP MIS LL. Performed
the experiments: AGT CP MS MN RDB TK LL. Analyzed the data:
WHL HS LL. Wrote the paper: HS LL.
References
1. Ponting CP, Aravind L (1999) START: a lipid-binding domain in StAR, HD-
ZIP and signalling proteins. Trends in Biochemical Science 24: 130–132.
2. Soccio RE, Breslow JL (2003) StAR-related lipid transfer (START) proteins:
mediators of intracellular lipid metabolism. Journal of Biological Chemistry 278:
22183–22186.
3. Alpy F, Tomasetto C (2005) Give lipids a START: the StAR-related lipid
transfer (START) domain in mammals. Journal of Cell Science 118:
2791–2801.
4. Barros MH, Johnson A, Gin P, Marbois BN, Clarke CF, et al. (2005) The
Saccharomyces cerevisiae COQ10 gene encodes a START domain protein
required for function of coenzyme Q in respiration. Journal of Biological
Chemistry 280: 42627–42635.
5. Tsujishita Y, Hurley JH (2000) Structure and lipid transport mechanism of a
StAR-related domain. Nature Structural Biology 7: 408–414.
6. Roderick SL, Chan WW, Agate DS, Olsen LR, Vetting MW, et al. (2002)
Structure of human phosphatidylcholine transfer protein in complex with its
ligand. Nature Structural Biology 9: 507–511.
7. Romanowski MJ, Soccio RE, Breslow JL, Burley SK (2002) Crystal structure of
the Mus musculus cholesterol-regulated START protein 4 (StarD4) containing a
StAR-related lipid transfer domain. Proceedings of the National Academy of
Sciences of the United States of America 99: 6949–6954.
8. Kudo N, Kumagai K, Tomishige N, Yamaji T, Wakatsuki S, et al. (2008)
Structural basis for specific lipid recognition by CERT responsible for
nonvesicular trafficking of ceramide. Proceedings of the National Academy of
Sciences of the United States of America 105: 488–493.
9. Kudo N, Kumagai K, Matsubara R, Kobayashi S, Hanada K, et al. (2010)
Crystal structures of the CERT START domain with inhibitors provide insights
into the mechanism of ceramide transfer. Journal of Molecular Biology 396:
245–251.
10. Murcia M, Faraldo-Gomez JD, Maxfield FR, Roux B (2006) Modeling the
structure of the StART domains of MLN64 and StAR proteins in complex with
cholesterol. Journal of Lipid Research 47: 2614–2630.
11. Soccio RE, Adams RM, Romanowski MJ, Sehayek E, Burley SK, et al. (2002)
The cholesterol-regulated StarD4 gene encodes a StAR-related lipid transfer
protein with two closely related homologues, StarD5 and StarD6. Proceedings of
the National Academy of Sciences of the United States of America 99:
6943–6948.
12. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from
crystalline state. Journal of Molecular Biology 372: 774–797.
13. Roostaee A, Barbar E, Lehoux JG, Lavigne P (2008) Cholesterol binding is a
prerequisite for the activity of the steroidogenic acute regulatory protein (StAR).
Biochemical Journal 412: 553–562.
14. Roostaee A, Barbar E, Lavigne P, LeHoux JG (2009) The mechanism of specific
binding of free cholesterol by the steroidogenic acute regulatory protein:
evidence for a role of the C-terminal alpha-helix in the gating of the binding site.
Bioscience Reports 29: 89–101.
Table 4. Refinement statistics.
Protein STARD1 STARD5 STARD13 STARD14
PDB entry 3P0L 2R55 2PSO 3FO5
Search model 1EM2 1JSS 1JSS -
Ligand ---P E G
Rwork
{/Rfree
{ 0.257/0.287 0.232/0.276 0.210/0.244 0.202/0.251
Molecules/a.u. 4232
No. atoms
Protein 6373 3292 4477 3813
Ligands ---5 6
Water -2 6 -1 6 8
B-factors (A ˚ 2)
Protein 128 78.8 90.1 39.6
Ligands ---4 0 . 0 8
Water - 51.1 - 28.5
R.m.s deviations
Bond lengths (A ˚) 0.002 0.012 0.011 0.013
Bond angles (˚
) 0.512 1.375 1.454 1.386
Ramachandran plot
(%)
Favored regions 92.3 93.6 90.1 98.7
Additionally
allowed regions
7.7 6.4 9.0 1.3
Outliers --0 . 9 -
{Rwork is defined as S ||Fobs |2|Fcalc || S |F obs |, where Fobs and Fcalc are observed
and calculated structure-factor amplitudes, respectively.
{Rfree is the R factor for the test set (5–10% of the data).
doi:10.1371/journal.pone.0019521.t004
Crystal Structures of Human START Domains
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e1952115. Bens S, Mohn A, Yuksel B, Kulle AE, Michalek M, et al. (2010) Congenital
lipoid adrenal hyperplasia: functional characterization of three novel mutations
in the STAR gene. Journal of Clinical Endocrinology and Metabolism 95:
1301–1308.
16. Bose HS, Sato S, Aisenberg J, Shalev SA, Matsuo N, et al. (2000) Mutations in
the steroidogenic acute regulatory protein (StAR) in six patients with congenital
lipoid adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism
85: 3636–3639.
17. Lavigne P, Najmanivich R, Lehoux JG (2010) Mammalian StAR-related lipid
transfer (START) domains with specificity for cholesterol: structural conserva-
tion and mechanism of reversible binding. Subcellular Biochemistry 51:
425–437.
18. Baker BY, Epand RF, Epand RM, Miller WL (2007) Cholesterol binding does
not predict activity of the steroidogenic acute regulatory protein, StAR. Journal
of Biological Chemistry 282: 10223–10232.
19. Rodriguez-Agudo D, Ren S, Hylemon PB, Redford K, Natarajan R, et al.
(2005) Human StarD5, a cytosolic StAR-related lipid binding protein. Journal of
Lipid Research 46: 1615–1623.
20. Suematsu N, Okamoto K, Shibata K, Nakanishi Y, Isohashi F (2001) Molecular
cloning and functional expression of rat liver cytosolic acetyl-CoA hydrolase.
European Journal of Biochemistry 268: 2700–2709.
21. Ishikawa K, Nagase T, Suyama M, Miyajima N, Tanaka A, et al. (1998)
Prediction of the coding sequences of unidentified human genes. X. The
complete sequences of 100 new cDNA clones from brain which can code for
large proteins in vitro. DNA Research 5: 169–176.
22. Kabsch W (1993) Automatic processing of rotation diffraction data from crystals
of initially unknown symmetry and cell constants. Journal of Applied
Crystallography 26: 795–800.
23. CCP4 (1994) The CCP4 suite: programs for protein crystallography. Acta
Crystallographica Section D-Biological Crystallography D50: 760–763.
24. Adams PA, Afonine PV, Bunko ´czi G, Chen VB, Davis IW, et al. (2010)
PHENIX: a comprehensive Python-based system for macromolecular structure
solution. Acta Crystallographica Section D-Biological Crystallography D66:
213–221.
25. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallographica Section D-Biological Crystallography D60: 2126–2132.
26. Vagin A, Teplyakov A (1997) MOLREP: an automated program for molecular
replacement. Journal of Applied Crystallography 30: 1022–1025.
27. Painter J, Merritt EA (2006) TLSMD web server for the generation of multi-
group TLS models. Journal of Applied Crystallography 39: 109–111.
28. Keegan RM, Winn MD (2008) MrBUMP: an automated pipeline for molecular
replacement. Acta Crystallographica Section D-Biological Crystallography D64:
119–124.
29. Stein N (2008) CHAINSAW: a program for mutating pdb files used as templates
in molecular replacement. Journal of Applied Crystallography 41: 641–643.
30. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Strotoni LC, et al.
(2007) Phaser crystallographic software. Journal of Applied Crystallography 40:
658–674.
31. Terwilliger TC, Berendzen J (1999) Automated MAD and MIR structure
solution. Acta Crystallographica Section D-Biological Crystallography 55:
849–861.
32. Terwilliger TC (2000) Maximum-likelihood density modification. Acta Crystal-
lographica Section D-Biological Crystallography 56: 965–972.
33. Perrakis A, Harkiolaki M, Wilson KS, Lamzin VS (2001) ARP/wARP and
molecular replacement. Acta Crystallographica Section D-Biological Crystal-
lography 57: 1445–1450.
34. Lovell SC, Davis IW, Arendall WB, 3rd, de Bakker PI, Word JM, Prisant MG,
Richardson JS, Richardson DC (2003) Structure validation by Calpha geometry:
phi,psi and Cbeta deviation. Proteins 50: 437–450.
35. Shatsky M, Nussinov R, Wolfson HJ (2004) A method for simultaneous
alignment of multiple protein structures. Proteins 56: 143–156.
36. Shatsky M, Dror O, Schneidman-Duhovny D, Nussinov R, Wolfson HJ (2004)
BioInfo3D: a suite of tools for structural bioinformatics. Nucleic Acids Research
32: W503–507.
37. Lehtonen JV, Still DJ, Rantanen VV, Ekholm J, Bjo ¨rklund D, et al. (2004)
BODIL: a molecular modeling environment for structure-function analysis and
drug design. Journal of Computer Aided Molecular Design 18: 401–419.
38. Bond CS, Schuttelkopf AW (2009) ALINE: a WYSIWYG protein-sequence
alignment editor for publication-quality alignments. Acta Crystallographica
Section D-Biological Crystallography 65: 510–512.
39. Liang J, Edelsbrunner H, Woodward C (1998) Anatomy of protein pockets and
cavities: measurement of binding site geometry and implications for ligand
design. Protein Science 7: 1884–1897.
40. Bose HS, Whittal RM, Ran Y, Bose M, Baker BY, et al. (2008) StAR-like
activity and molten globule behavior of StARD6, a male germ-line protein.
Biochemistry 47: 2277–2288.
41. Wirtz KW (1991) Phospholipid transfer proteins. Annual Review of Biochem-
istry 60: 73–99.
42. Horibata Y, Sugimoto H (2010) StarD7 mediates the intracellular trafficking of
phosphatidylcholine to mitochondria. Journal of Biological Chemistry 258:
7358–7365.
43. Olayioye MA, Vehring S, Muller P, Herrmann A, Schiller J, et al. (2005)
StarD10, a START domain protein overexpressed in breast cancer, functions as
a phospholipid transfer protein. Journal of Biological Chemistry 280:
27436–27442.
Crystal Structures of Human START Domains
PLoS ONE | www.plosone.org 11 June 2011 | Volume 6 | Issue 6 | e19521